Primer: argenx (ARGX BB) - Aug 2026
Dominant Immunology Innovator: argenx has established itself as a leader in severe autoimmune diseases, driven by its first-in-class FcRn...
89 Views
No more insights
𝛼SK or SearchENTITY
argenx (ARGX BB)
argenx (ARGX BB)
1
Analysis
Health Care • Netherlands
argenx is a global immunology company focused on developing and commercializing antibody-based medicines for severe autoimmune diseases. Its flagship product, VYVGART (efgartigimod), is approved for generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is headquartered in Amsterdam, the Netherlands, and was founded in 2008.
morex